Patricia J A M Brouwers1, Erik van Werkhoven2, Harry Bartelink2, Alain Fourquet3, Claire Lemanski4, Judith van Loon5, John H Maduro6, Nicola S Russell2, Luc J E E Scheijmans7, Dominic A X Schinagl8, Antonia H Westenberg9, Philip Poortmans7, Liesbeth J Boersma5. 1. Department of Radiation Oncology, Maastricht University Medical Center, GROW (MAASTRO), The Netherlands. Electronic address: patricia.brouwers@maastro.nl. 2. Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 3. Department of Radiation Oncology, Institut Curie, UCBG, Paris, France. 4. Department of Radiation Oncology, Institut Régional du Cancer Val d'Aurelle, UCBG, Montpellier, France. 5. Department of Radiation Oncology, Maastricht University Medical Center, GROW (MAASTRO), The Netherlands. 6. Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 7. Department of Radiation Oncology, Institute Verbeeten, Tilburg, The Netherlands. 8. The Netherlands Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands. 9. Department of Radiation Oncology, Radiotherapiegroep, Arnhem, The Netherlands.
Abstract
PURPOSE: To investigate which factors are related to patient reported cosmetic outcome (PRCO) after breast conserving therapy. METHODS:From 2004 to 2011, 2421 cT1-2N0-2a breast cancer patients were randomised in the Young Boost Trial between a 16 and a 26Gy boost to the tumour bed. Cosmesis was scored subjectively by the patient and physician, and objectively using BCCT.core, at baseline, one and four years after treatment. Presence of fibrosis, QoL and rib pain at four years were also scored. Data were complete for 864 patients. The relation between the separate components was investigated using a proportional odds model. RESULTS: Of the 7 BCCT.core parameters, the distance from nipple to inframammary fold and the length of the breast contour were significantly related to the overall PRCO at four years. Patients with more fibrosis and poorer QoL scored their cosmesis worse, while rib pain was not related. The agreement between the different scores was low (kappa 0.26-0.42). CONCLUSION: The distance from nipple to inframammary fold, the length of the breast contour and the severity of fibrosis were the main factors related to patient-reported cosmetic outcome. Patients with better QoL scored their cosmesis better.
RCT Entities:
PURPOSE: To investigate which factors are related to patient reported cosmetic outcome (PRCO) after breast conserving therapy. METHODS: From 2004 to 2011, 2421 cT1-2N0-2a breast cancerpatients were randomised in the Young Boost Trial between a 16 and a 26Gy boost to the tumour bed. Cosmesis was scored subjectively by the patient and physician, and objectively using BCCT.core, at baseline, one and four years after treatment. Presence of fibrosis, QoL and rib pain at four years were also scored. Data were complete for 864 patients. The relation between the separate components was investigated using a proportional odds model. RESULTS: Of the 7 BCCT.core parameters, the distance from nipple to inframammary fold and the length of the breast contour were significantly related to the overall PRCO at four years. Patients with more fibrosis and poorer QoL scored their cosmesis worse, while rib pain was not related. The agreement between the different scores was low (kappa 0.26-0.42). CONCLUSION: The distance from nipple to inframammary fold, the length of the breast contour and the severity of fibrosis were the main factors related to patient-reported cosmetic outcome. Patients with better QoL scored their cosmesis better.
Authors: M J Cambra; F Moreno; X Sanz; L Anglada; M Mollà; V Reyes; M Arenas; A Pedro; R Ballester; V García; J Casals; M Cusidó; C Jimenez; J M Escribà; M Macià; J M Solé; A Arcusa; M A Seguí; S Gonzalez; B Farrús; A Biete Journal: Clin Transl Oncol Date: 2019-07-01 Impact factor: 3.405
Authors: J Sanz; N Rodríguez; P Foro; J Dengra; A Reig; P Pérez; I Membrive; A Ortiz; M Codinach; M Algara Journal: Clin Transl Oncol Date: 2016-09-21 Impact factor: 3.405
Authors: D B Raphael; N S Russell; J M Immink; P G Westhoff; M C Stenfert Kroese; M R Stam; L M van Maurik; H J G D van den Bongard; J H Maduro; M G A Sattler; T van der Weijden; L J Boersma Journal: Breast Date: 2020-04-06 Impact factor: 4.380